Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Endo Gets Surprise Aveed Approval, But REMS Could Be A Roadblock

This article was originally published in The Pink Sheet Daily

Executive Summary

After seven years of rejection, Endo finally gets FDA’s go-ahead on its long-acting testosterone treatment, but a strict REMS program and plenty of market competitors will make the drug’s launch difficult.

You may also be interested in...



Oral Testosterones Might Use REMS, CV Post-Market Study To Win Approval

US FDA advisory committee worries about off-label use of Lipocine's Tlando and Clarus' Jatenzo.

Testosterone Replacement Safety Gets FDA Panel Review As Lawsuits Pile Up

Two advisory committees will discuss appropriate population for testosterone treatment and potential for adverse cardiovascular outcomes; product liability suits have been consolidated in Illinois federal court.

Endo Follows Valeant’s Strategy Of Growth Through Acquisition

The specialty pharma’s CFO highlighted Endo’s recent restructuring and talked about its plans for M&A going forward at a recent health care conference.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS077053

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel